Why is Astrazeneca Phar falling/rising?

As of 05-Aug, Astrazeneca Pharma India Ltd's stock price is currently at 8,850.00, reflecting a decrease of 125.05, or 1.39%. Today's price summary indicates that the stock opened with a loss of 2.5% and reached an intraday low of Rs 8750.75. The stock has underperformed its sector by 0.44%, and there has been a significant drop in investor participation, with delivery volume falling by 69.47% compared to the 5-day average. Despite a strong year-to-date return of 20.66% and a 29.31% increase over the past year, the stock's recent performance has been hindered by a poor long-term growth outlook, as indicated by a 15.95% annual growth rate in operating profit over the last five years and a high valuation compared to peers.
In the broader market context, Astrazeneca's short-term performance has lagged behind the benchmark, with a 1-week return of -1.30% compared to the Sensex's -0.77%. While the company has demonstrated high management efficiency and consistent returns over the past three years, the high price-to-book ratio and a PEG ratio of 3.1 suggest that the stock may be overvalued, contributing to its recent decline. The combination of these factors, including a significant drop in trading volume and a challenging valuation environment, has led to the stock's current downward movement.